By late 2025, an estimated 3040 million Americans (~1012.5% of adults) were taking GLP-1 drugs ( [1] ) ( [2] )
We should emphasize that BPC 157 (as described (4-9)) avoids all the practical pitfalls for fistula healing using peptidergic growth factors (i.e., standard growth factors would hardly combine skin and gastrointestinal ulcer healing due to the different way of administration and drug delivery to gastrointestinal ulcer and skin ulcer (26, 27))
In the DCCTEDIC follow-up study, delayed gastric emptying was associated with other complications of diabetes, particularly severe retinopathy, and to a lesser extent with cardiovascular vagal dysfunction and severe nephropathy [28]
Chris Shaver explain why some people taking GLP-1 medications may experience foul-smelling burps and bad breath, how gastroparesis can play a role, and whats actually happening inside the digestive tract
Albright, B
As these combinations move toward approval, oral formulations may follow